Lee GC, Dallas SD, Wang Y, Olsen RJ, Lawson KA, Wilson JP, Frei CR, “Emerging Multidrug Resistance in Community-Associated Staphylococcus Aureus Involved in Skin and Soft Tissue Infections and Nasal Colonization,” Journal of Antimicrobial Chemotherapy, July 3, 2017, doi: https://doi.org/10.1093/jac/dkx200, (8 pages).
Attridge RT, Frei CR, Pugh MJ, Lawson KA, Ryan L, Anzueto A, Metersky ML, Restrepo MI, Mortensen EM, “Healthcare-associated Pneumonia in the ICU: Guideline-concordant Antibiotics and Outcomes,” Journal of Critical Care, December 2016; 36: 265-271.
Lee GC, Hall RG, Boyd NK, Dallas SD, Du LC, Trevino LB, Retzloff C, Trevino SB, Lawson KA, Wilson JP, Olsen RJ, Wang Y, Frei CR, “Predictors of community-associated Staphylococcus aureus, methicillin resistant- and methicillin-susceptible- Staphylococcus aureus skin and soft tissue infections in primary care settings,” Epidemiology and Infection, August 2016; Epub ahead of print, doi 10.1017/S0950268816001709.
Olotu BS*, Shepherd MD, Novak S, Lawson KA, Wilson JP, Richards KM, Rasu RS, “Use of Statins and the Risk of Incident Diabetes: A Rertrospective Cohort Study,” American Journal of Cardiovascular Drugs, June 7, 2016, Epub ahead of print, doi 10.1007/s40256-016-0176-1, http://link.springer.com/article/10.1007/s40256-016-0176-1.
Campbell AH, Scalo JF*, Crismon ML, Barner JC, Argo TR, Lawson KA, and Miller AL, “Attitudes toward Medications and the Relationship to Outcomes in Patients with Schizophrenia,” Clinical Schizophrenia and Related Psychoses, in press, July 28, 2015, Epub ahead of print, http://dx.doi.org/10.3371/CSRP.CASC.070415.
Shcherbakova N, Rascati K, Brown C, Lawson K, Novak S, Richards KM, and Yoder L, “Factors Associated with Seizure Recurrence in Epilepsy Patients Treated with Antiepileptic Monotherapy: A Retrospective Observational Cohort Study using US Administrative Insurance Claims,” CNS Drugs, November 2014; 28(11): 1047-1058.
Park C*, Jiang S*, and Lawson KA, “Efficacy and Safety of Telaprevir and Boceprevir in Patients with Hepatitis C Genotype 1: A Meta-Analysis,” Journal of Clinical Pharmacy and Therapeutics, February 2014; 39(1): 14-24.
Lee GC*, Lawson KA, and Burgess D, “Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae in Community Hospitals: A Case-Case-Control Study,” The Annals of Pharmacotherapy, September 2013; 47(9): 1115-1121.
Attridge RT*, Frei CR, Restrepo MI, Lawson KA, Ryan L, Pugh MJV, Anzueto A, and Mortensen EM, “Guideline-Concordant Therapy and Outcomes in Healthcare-Associated Pneumonia,” European Respiratory Journal, October 1, 2011; 38(4): 878-887 (published online on March 24, 2011 DOI: 10.1183/09031936.00141110, 2011. [PMID: 21436359]).
Nduaguba SO,* Okoh C,* Barner JC, Ford KC, Wilson JP, Lawson KA, Barnes JN, Beretvas T, “Comparative Effectiveness of Efavirenz and Protease Inhibitors in Patients with Human Immunodeficiency Virus – A Meta-Analysis,” International Conference for Pharmacoepidemiology Annual Meeting, Philadelphia, PA, August 24 – 28, 2019.
Park C, Lawson KA, Barner JC, Powers DA, Rascati KL, Wilson JP, “Comorbidity Measures to Predict Overall Survival Time among Elderly Gynecologic Cancer Survivors in the U.S.: An Analysis of SEER-Medicare Data,” International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting, Boston, MA, May 20-24, 2017 (published abstract PCN9, Value in Health, May 2017; 20(5): A88).
Nduaguba S, Wilson J, Ford K, Lawson KA, “Identifying At-Risk Subgroups Living with HIV: A Survival Analysis,” American Public Health Association 2016 Annual Meeting and Expo, Denver, CO, November 1, 2016 (abstract number 347897).
Thach AV*, Brown CM, Herrera V, Sasane R, Barner JC, Ford KC, Lawson KA. “Associations between Treatment Satisfaction, Medication Beliefs, and Adherence to Disease Modifying Therapies in Patients with Multiple Sclerosis,” 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), London, England, September 14-17, 2016.
Desai P*, Lawson KA, Richards KM, Rascati KL, Barner JC, Miller A, “Assessing Factors Associated with Antipsychotic Polypharmacy in the Texas Medicaid Population,” International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting, Washington, DC, May 22-25, 2016 (published abstract PMH80, Value in Health, May 2016; 19(3): A196).
Singh RR*, Lawson KA, Barner JC, Richards KM, Sasane R, Wilson JP, “Prevalence and Incidence of Attention Deficit Hyperactivity Disorder among Texas Medicaid Preschoolers,” International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting, Washington, DC, May 22-25, 2016 (published abstract PMH23, Value in Health, May 2016; 19(3): A185).
Park C*, Grebla R, Richards KM, Setyawan J, Pawaskar M, Erder MH, Lawson KA. “Modeling Treatment Response in Attention Deficit Hyperactivity Disorder among Children and Adolescents in the Texas Medicaid Population,” American Academy of Child & Adolescent Psychiatry, San Antonio, TX, October 2015.
Richards KM, Lawson KA, Nazareth T, Yu T-C, Ko JJ, Burton E, Sasane R, “Differences in Patient Characteristics, Disease-Modifying Treatment Utilization, and Relapse by Race/Ethnicity in Texas Medicaid Patients with Multiple Sclerosis,” 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Barcelona, Spain, October 7-10, 2015.
Park C*, Kim G*, Jiang S*, and Lawson KA, “The Association of Comorbid Anxiety and Mood Disorders with Health-related Quality of Life among Cancer Survivors,” International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (published abstract PCN156, Value in Health, May 2014; 17(3): A95).